Development strategy and clinical research progress of universal chimeric antigen receptor T-cell drugs
10.11665/j.issn.1000-5048.20211125001
- VernacularTitle:通用型CAR-T细胞药物的开发策略及临床研究进展
- Author:
Chen WANG
1
;
ZHANG ZHANG
;
Yinchun LI
Author Information
1. 正大天晴药业集团股份有限公司研究院
- Publication Type:Journal Article
- Keywords:
CAR-T;
allogeneic;
immune rejection;
gene editing;
clinical research;
progress
- From:
Journal of China Pharmaceutical University
2023;54(2):141-149
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor T-cell (CAR-T) immunotherapy has made a breakthrough in the clinical treatment of a variety of hematological tumors.However, the CAR-T cell products listed at China and abroad are all autologous CAR-T.Compared with autologous CAR-T treatment, universal CAR-T exhibits significant advantages, which could fulfill the treatment demand of more patients, but also displays high technical barriers.This paper reviews the universal CAR-T, clearly points out the two major challenges faced by the development of universal CAR-T, and then summarizes and analyzes the feasible solutions according to the mechanism causing the two major problems.This paper also summarizes domestic and foreign companies producing universal CAR-T and the latest clinical progress of their superior products, and then discusses the feasibility of the development strategy from another aspect, in order to provide ideas for developing a new generation of universal CAR-T cell therapy products.
